Recent Posts
Connect with:
Friday / June 21.
HomeminewsZeiss First OCT Angiography

Zeiss First OCT Angiography

Zeiss Medical Technology has launched AngioPlex OCT Angiography at RANZCO 2015 in Wellington. This is the first such technology to receive 510(k) clearance from the U.S. Food and Drug Administration (FDA).[/vc_column_text][/vc_column]

AngioPlex OCT Angiography, available on the CIRRUS 5000 HD-OCT platform, delivers high-resolution, depth-resolved visualisation of the separate layers of the retinal and choroidal vasculature, without the need for an injected contrast dye, as is standard with fluorescein angiography (FA).

The information provided by these images is clinically impactful because progression of retinal diseases is often accompanied by changes in the vasculature of the eye. According to Zeiss, in age-related macular degeneration (AMD), diabetic retinopathy, central retinal vein occlusion and other vascular conditions, AngioPlex OCT Angiography can complement traditional FA and become a safe and efficient part of routine eye care, potentially enabling earlier detection and management of micro-progressions.

AngioPlex OCT Angiography clearly visualises blood flow by detecting motion of scattering particles, such as red blood cells, within sequential OCT B-scans performed repeatedly at the same location of the retina. CIRRUS HD-OCT with AngioPlex only requires a single additional OCT scan as the real-time retinal tracking system, FastTrac, actively eliminates eye motion to provide motion-artifact-free images of the perfused retina. FastTrac also enables follow-up OCT angiography images to be acquired at the same precise location in order to assess treatment efficacy and monitor disease progression.

CE Marking is pending from the European Union.